Respiratory Tract Infection: Ketek Now FDA-Approved

January 1, 2007

Telithromycin (Ketek) from AventisPharmaceuticals Inc., is now availableto treat acute exacerbations of chronicbronchitis, acute bacterial sinusitis,and mild to moderately severe community-acquired RTI-includingthose caused by multidrug-resistantStreptococcus pneumoniae. Telithromycin,the first available ketolide, selectivelytargets common respiratorybacteria without significant effects onbacteria not normally associated withRTIs.

New Agent CombatsRespiratory Tract InfectionTelithromycin (Ketek) from AventisPharmaceuticals Inc., is now availableto treat acute exacerbations of chronicbronchitis, acute bacterial sinusitis,and mild to moderately severe community-acquired RTI--includingthose caused by multidrug-resistantStreptococcus pneumoniae. Telithromycin,the first available ketolide, selectivelytargets common respiratorybacteria without significant effects onbacteria not normally associated withRTIs.The recommended dosage is800 mg/d. Telithromycin is not approvedfor those younger than 18years. The most common side effectsare diarrhea, nausea, headache, dizziness,and vomiting.